Poltreg S.A. attended the meeting ‘Business in the Genes’ at the Warsaw Stock Exchange. We presented the progress of the company and reported accomplishment of phase II study in type 1 diabetes and phase I in multiple sclerosis. We also showed our current preparatory work on pivotal phase III study in type 1 diabetes in Eurpe and USA. We have also informed about hospital exemption procedure, which allows us to offer the therapy in the University Hospital in Gdańsk. The first patients were administered with the preparation already. Finally, we discussed current financial needs of the company and the progress of the fundraising to date.
Prof. Trzonkowski presented the lecture ‘Treatment of autoimmune diseases with T regulatory cells in humans – promises and hurdles’ during the workshop ‘Discovery to clinical applications of regulatory T cells in autoimmunity and transplantation’ organized by the British Society of Immunology.
The patient’s trust award ‘Złoty Otis’ for her achievements in endocrinology and diabetology to Prof. Myśliwiec
Prof. Myśliwiec elected again to be the member of the Board of the Polish Society of Diabetology for the term 2019-2023.
The Award of the Polish Society of Diabetology to Prof. Myśliwiec for Her spectacular achievements in the clinical and experimental science in diabetology. The ceremony took place during the the XX Congress of the Polish Society of Diabetology in Lublin, in which prof. Myśliwiec gave the inaugural Jakub Węgierka’s lecture: ‘Running for success in diabetology’.
Scientists from Poltreg presented their academic and commercial experience with the Tregs at the TREG SUMMIT in Boston.
Poltreg presented its current strategy at LSX World Congress in London. The Congress is a high-calibre, senior executive, conference, exhibition and partnering event providing the education, strategies, solutions and contacts that life science executives need to enable more effective investment, planning and strategic growth within their businesses.
Prof. Piotr Trzonkowski gave a lecture on TREG method during European Congress of Immunology in Amsterdam. The congress is the biggest and the most important European event on immunology taking place every three years in different European cities.
PolTREG has been awarded 2 500 000 Euro grant in Horizon2020 in the healthcare biotechnology sector.(project 830559 – TREG: TREG – innovative cell therapy targeting Diabetes Type 1). We are the only Polish SME company that received support in this instrument in the area of healthcare. The money will be spent on the preparations to phase III clinical trial in type 1 diabetes.
Report on adverse effects from clinical trials on type 1 diabetes and multiple sclerosis confirmed good safety profile of the treatment.
Scientists from Poltreg are co-authors of the minimum information model on Treg cell therapy (MiTREG). The paper describing MiTREG brought together over 50 scientists from all over the world.
Last patient recruited into phase I trial on multiple sclerosis in STRATEGMED TREGS programme. Full results of the study will be available in second quarter of 2019.
Inventor of TREG method Prof. Piotr Trzonkowski has received the Foundation for Polish Science Prize 2017 in the life and earth sciences for studies on regulatory T cells and their pioneering use in cell therapy of human diseases. This is the most important scientific prize in Poland.
Last patient recruited into phase II trial on type 1 diabetes in STRATEGMED TREGS programme. Full results of the study will be available in third quarter of 2019.
Scientists from Poltreg took a part in the final meeting of the “Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies (AFACTT). This is Europe’s Biggest Research Network on cell-based tolerance-inducing therapies that brings together around 100 scientists from 20 European universities.
Scientists from Poltreg published report with new data on laboratory technique increasing stability and quality of TREG preparation used in the treatment. The method is a subject of new patent application.
Scientists from Poltreg published report describing long-term effects of the therapy. The report proves that the patients treated with TREG cells could produce insulin more than 2 years after administration of the preparation.